Drug Interactions between Flucelvax and zoster vaccine live

The safety and efficacy of concomitant administration of varicella-zoster virus (VZV) vaccine and trivalent inactivated influenza vaccine in adults aged 50 and older were demonstrated in a large randomized, controlled study conducted at 20 sites in the U.S. and Europe. The study compared 382 subjects who received the vaccines simultaneously at separate injection sites (vaccines on day one; placebo at week 4) to 380 subjects who received them sequentially (influenza vaccine and placebo on day one; VZV vaccine at week 4) and found no significant difference in antibody responses between the two groups. Four weeks postvaccination, VZV antibody geometric mean titers were 554 gpELISA units/mL for the concomitant group and 597 gpELISA units/mL for the sequential group. The estimated geometric mean titre ratios (concomitant/sequential) were 0.9 for influenza A (H1N1), 1.1 for influenza A (H3N2), and 0.9 for influenza B according to hemagglutination inhibition assay. Both concomitant and sequential administration were generally well tolerated, with a similar overall incidence of systemic adverse events of approximately 33% and vaccine-related systemic adverse events of approximately 5% within four weeks postvaccination.